TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: percentage endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incisional corneal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile (LDL, total cholesterol, triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unfavorable outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of activated peripheral T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-oxLDL antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normalization of serum phosphate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative VAS score for stump pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intake of opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker Faces scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' assessments of procedural pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of positive culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CFU (Colony Forming Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: scholastic performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: behavioral outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: neurocognitive attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of body weight decrease at postoperative day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall thrombosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: severe adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: low-birth-weight infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Grade 4 toxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3-4 nail disorders, hand-foot syndrome and peripheral neuropathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Aminotransferases level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Analgesic tablet consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CRRT dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for detecting fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Website use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IL-8 concentration change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean decrease in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: collecting system injury rates
Endpoint domain: Adverse events/effects
Primary endpoint: hospitalization times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: incidence of GI bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of freezes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum gastrin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum chromogranin A level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean VAS score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Rates of reactogenicity events and vaccine-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events or influenza-like illness
Endpoint domain: Adverse events/effects
Primary endpoint: 4-fold rise in influenza antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of high-risk MTX concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Delay in resuming continuation chemotherapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: FV waste
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variety of FV selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of acceptance for COPD screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subsequent suicide attempts
Endpoint domain: Adverse events/effects
Primary endpoint: dropout rate
Endpoint domain: Resource use
Primary endpoint: HAMD score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cost of immunostimulating treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Q allele frequency of R353Q polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of factor II (G20210A) and factor V (G1691A) mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term effectiveness of corticosteroid injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month SF-36 physical component summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: one-year occurrence of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of ER-positive invasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of deep-vein thrombosis and pulmonary embolism
Endpoint domain: Adverse events/effects
Primary endpoint: overall treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOL rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interproximal clinical attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esthetic appraisal by the patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adherence to scheduled follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Activation of dendritic Langerhans cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Generation of interleukin‐10‐producing regulatory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suppression of autoreactive proliferative responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: related psychopathology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of oedema
Endpoint domain: Adverse events/effects
Primary endpoint: Progressive field loss on SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Hb modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prognostication of CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prognostication of spontaneous MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain perception during palatal infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVIIa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Global Impression Scale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily mean CPRS‐R:S total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of offences
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of pupils experiencing a heavy drinking episode avoided
Endpoint domain: Adverse events/effects
Primary endpoint: Public sector costs
Endpoint domain: Resource use
Primary endpoint: systolic blood pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of survival at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Rate of grades 3-5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-reported pain on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of uterine scar defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fat mtDNA content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complex I activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complex IV activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local-regional cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: erosion rate of silastic
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported physical function improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in buccal vertical height relative to baseline crestal width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of respiratory morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: BMI change post-cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: group membership and participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: emotional support seeking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of abnormal TID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity for detecting severe CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: glycemia level (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total antioxidative plasma capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median numbers of active lesions per patient per scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: accumulation of BOD (percent change from baseline to month 36)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increase in physical activity (PA) measured in steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on the incongruent stroop task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: shear bond strength to enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal wavefront aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Therapeutic failure
Endpoint domain: Mortality/survival
Primary endpoint: Plasma HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Odds of seeing a provider for asthma-like symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decreased behavioral problems (ECBI Intensity)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreased emotional symptoms (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rate of CIDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plt levels before and after liver transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P‐TPO levels before and after liver transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of cerebral vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pulse rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADHD and oppositional symptoms rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative whole-body scintigraphy (WBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroglobulin-stimulated levels <1.0 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate blood pressure control (< 140/90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL‐cholesterol < 100 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: good body-mass index (< 25)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: JRS errors in flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: JRS errors in external rotation (ER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean VA gain over baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean optical coherence tomography central subfield thickness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Hcy level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improvements in bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: late loss of luminal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: restenosis of more than 50 percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target BP levels reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mucosal-plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: composite wound morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of viable tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUSH scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Moderate to severe cognitive deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: auditory processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inferoseptal to lateral wall delay in peak strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: therapy discontinuation rate
Endpoint domain: Adverse events/effects
Primary endpoint: IBS-severity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cost differences per patient
Endpoint domain: Resource use
Primary endpoint: frontal cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: multiple chronic morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: technology dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean increase in morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: days without asthma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: duration of good asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding Time (BT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discoloration of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faster ileal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shorter total procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of cortexin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of cortexin treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Net monetary benefit of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Infant and maternal toxicities or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Infant creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of risk perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: size of ulcers decreased
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete healing of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrent cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of heterotopic ossification (HO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal gingival coloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: core fragmentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain control
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Serious adverse events related to surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of PIVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Activities of vitamin K-dependent coagulation factors II, VII, and X
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sustained Ara h 2-specific IgG4 antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative urine cannabinoid test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for suture closure over staples
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Glycemic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatal and non-fatal cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detrusor overactivity abolition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HFMD
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of absence due to sickness (in days)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Episodes of absence due to respiratory, skin and eye infections
Endpoint domain: Adverse events/effects
Primary endpoint: influence of a‐PM on u‐PM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: influence of a‐PM on a‐M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reaction time and lapses (PVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation in lane position and speed (AusEd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total propofol administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes